Orthopaedic Implant Company launches DRPx System after FDA clearance
The FDA granted clearance for the DRPx System, a new wrist fracture plating technology, from the Orthopaedic Implant Company, according to a company press release.
“A new standard needs to be set clinically and financially in orthopedics, and that's what we're doing with DRPx,” Itai Nemovicher, CEO of the Orthopaedic Implant Company, said in the release. “DRPx can compete with the most feature-rich distal radius plates on the market. It is engineered to support exceptional clinical outcomes and reduce costs while providing surgeons with much-needed familiarity and flexibility when it comes to technique.”
The system was designed with type II anodized titanium and features pre-contoured anatomic plates and a distal window for graft and fracture visualization. This system is intended to be an affordable tool for ASCs and hospitals.